argenx SE

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
ICLRICON plc -0.09%190.842.7%$94.76m
ARGXargenx SE -3.79%343.200.0%$74.92m
VRXValeant Pharmaceuticals International, Inc. -1.26%7.0614.1%$41.54m
BRBRBellRing Brands, Inc. -0.18%21.710.0%$20.03m
RVMDRevolution Medicines, Inc. 0.11%18.430.0%$16.82m
BGXXBright Green Corp. 1.63%1.250.0%$6.91m
USNAUSANA Health Sciences, Inc. -0.33%58.354.2%$3.68m
ANIKAnika Therapeutics, Inc. 0.04%23.479.7%$1.99m
ENVBEnveric Biosciences, Inc. -3.40%4.540.0%$0.62m
IBIOiBio, Inc. -6.76%0.350.2%$0.60m
NATRNature's Sunshine Products, Inc. -1.60%8.610.4%$0.42m
FLGCFlora Growth Corp. -3.51%0.880.0%$0.34m
BPTSBiophytis SA 0.00%0.660.0%$0.31m
GHSIGuardion Health Sciences, Inc. 7.99%0.150.0%$0.24m
CDXCChromadex Corp. -6.20%1.212.7%$0.19m

Company Profile

argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.